Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Roberto Ruiz

Internal Medicine Phoenix, AZ Medical Doctor

NPI 1770578148 CMS profile 79933

15255 N 40Th St, Suite 127, Phoenix, AZ 85032

Open in the dashboard

General payments

$25,423

281 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Roberto Ruiz of Phoenix, AZ is reported in the CMS Open Payments database as having received $25,423 across 281 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $34 2
2022 General $37 2
2021 General $386 7
2020 General $1,925 101
2019 General $23,041 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberto Ruiz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Roberto Ruiz were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Roberto Ruiz Internal Medicine median Middle half National median
2019 $23,041 $159 $48–$570 $163
2020 $1,925 $119 $33–$402 $114
2021 $386 $135 $37–$521 $132
2022 $37 $141 $42–$496 $149
2023 $34 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Merck Sharp & Dohme Corporation $10,738 28 payments
  2. Kowa Pharmaceuticals America, Inc. $8,294 60 payments
  3. Sanofi-Aventis U.S. LLC $2,791 33 payments
  4. AstraZeneca Pharmaceuticals LP $652 22 payments
  5. Allergan Inc. $629 28 payments
  6. Novo Nordisk Inc $343 27 payments
  7. Abbott Laboratories $326 9 payments
  8. Lilly USA, LLC $271 11 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $251 14 payments
  10. Genentech USA, Inc. $149 1 payment
  11. Other $981 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,860 4 payments
  2. Honoraria $6,000 3 payments
  3. Food and Beverage $5,743 257 payments
  4. Travel and Lodging $4,393 13 payments
  5. Consulting Fee $2,372 1 payment
  6. Education $55 3 payments
Products named General payments · program years 2019–2023
  1. STEGLATRO $10,738 28 payments
  2. SOLIQUA 100/33 $2,372 1 payment
  3. Livalo $1,489 54 payments
  4. Bystolic $404 42 payments
  5. FARXIGA $381 16 payments
  6. BOTOX $369 5 payments
  7. TRULICITY $271 11 payments
  8. JARDIANCE $213 12 payments
  9. Ozempic $210 13 payments
  10. Tresiba $209 10 payments
  11. Other $3,456 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record